In support of the potential oncogenic role of PELI3 in NSCLC, our Kaplan–Meier’s analysis demonstrated the more favorable prognosis associated with low PELI3 level in the NSCLC patients (Fig. 1e). This evidence concerns the gene PELI3 and non-small cell lung carcinoma.